141 related articles for article (PubMed ID: 30742720)
1. Surveillance for familial melanoma: recommendations from a national centre of expertise.
Halk AB; Potjer TP; Kukutsch NA; Vasen HFA; Hes FJ; van Doorn R
Br J Dermatol; 2019 Sep; 181(3):594-596. PubMed ID: 30742720
[No Abstract] [Full Text] [Related]
2. [Molecular diagnostics in melanoma].
Lang R; Bauer JW; Laimer M
Hautarzt; 2015 Apr; 66(4):277-81. PubMed ID: 25783213
[TBL] [Abstract][Full Text] [Related]
3. BRAF mutation testing in melanoma: results from a German observational multicenter study.
Hartmann A; Schirmacher P; Sterlacci W; Koch W; Liesenfeld DB; Schif B; Garbe C
Virchows Arch; 2019 Jan; 474(1):71-78. PubMed ID: 30406424
[TBL] [Abstract][Full Text] [Related]
4. Does assessment of family history of melanoma provide valid information?
Pasquini P
Arch Dermatol; 1999 Dec; 135(12):1527-8. PubMed ID: 10606060
[No Abstract] [Full Text] [Related]
5. Multiple primary melanomas versus single melanoma of the head and neck: a comparison of genetic, diagnostic, and therapeutic implications.
Pollio A; Tomasi A; Pellacani G; Ruini C; Mandel VD; Fortuna G; Seidenari S; Ponti G
Melanoma Res; 2014 Jun; 24(3):267-72. PubMed ID: 24638154
[TBL] [Abstract][Full Text] [Related]
6. A Large Skin-colored Nodule on the Plantar Foot: A Quiz. Melanoma associated with germline BAP1 mutation.
Rojek NW; Korcheva V; Leachman SA
Acta Derm Venereol; 2017 Nov; 97(10):1265-1266. PubMed ID: 28597019
[No Abstract] [Full Text] [Related]
7. Primary cutaneous angiomatoid melanoma.
Fonda-Pascual P; Moreno-Arrones OM; Alegre-Sanchez A; Garcia-Del Real CM; Miguel-Gomez L; Martin-Gonzalez M
J Dtsch Dermatol Ges; 2018 Mar; 16(3):345-347. PubMed ID: 29389063
[No Abstract] [Full Text] [Related]
8. Childhood melanoma: what every pediatrician should know.
Dinulos J
Curr Opin Pediatr; 2009 Aug; 21(4):472-4. PubMed ID: 19617832
[No Abstract] [Full Text] [Related]
9. Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients.
Mantelli M; Pastorino L; Ghiorzo P; Barile M; Bruno W; Gargiulo S; Sormani MP; Gliori S; Vecchio S; Ciotti P; Sertoli MR; Queirolo P; Goldstein AM; Bianchi-Scarrà G;
Melanoma Res; 2004 Dec; 14(6):443-8. PubMed ID: 15577313
[TBL] [Abstract][Full Text] [Related]
10. Neurofibromin protein loss in desmoplastic melanoma subtypes: implicating NF1 allelic loss as a distinct genetic driver?
Kadokura A; Frydenlund N; Leone DA; Yang S; Hoang MP; Deng A; Hernandez-Perez M; Biswas A; Singh R; Yaar R; Mahalingam M
Hum Pathol; 2016 Jul; 53():82-90. PubMed ID: 26980030
[TBL] [Abstract][Full Text] [Related]
11. Skin Cancer Associated Genodermatoses: A Literature Review.
Schierbeck J; Vestergaard T; Bygum A
Acta Derm Venereol; 2019 Apr; 99(4):360-369. PubMed ID: 30653245
[TBL] [Abstract][Full Text] [Related]
12. Melanoma diagnosis during periodic surveillance of patients with multiple atypical naevi.
Rauwerdink DJW; Roach REJ; Etty MA; Kukutsch NA; van Doorn R
Br J Dermatol; 2018 Oct; 179(4):997-998. PubMed ID: 29704460
[No Abstract] [Full Text] [Related]
13. Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report.
Ashida A; Uhara H; Mikoshiba A; Sakaizawa K; Kumagai N; Koga H; Okuyama R
Acta Derm Venereol; 2016 Jan; 96(1):128-9. PubMed ID: 26123241
[No Abstract] [Full Text] [Related]
14. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
O'Brien O; Lyons T; Murphy S; Feeley L; Power D; Heffron CCBB
J Clin Pathol; 2017 Nov; 70(11):935-940. PubMed ID: 28424234
[TBL] [Abstract][Full Text] [Related]
15. Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
[TBL] [Abstract][Full Text] [Related]
16. Novel mutations identified by whole-exome sequencing in acral melanoma.
Lim Y; Yoon D; Lee DY
J Am Acad Dermatol; 2020 Dec; 83(6):1792-1794. PubMed ID: 32278801
[No Abstract] [Full Text] [Related]
17. CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
Betti M; Aspesi A; Biasi A; Casalone E; Ferrante D; Ogliara P; Gironi LC; Giorgione R; Farinelli P; Grosso F; Libener R; Rosato S; Turchetti D; Maffè A; Casadio C; Ascoli V; Dianzani C; Colombo E; Piccolini E; Pavesi M; Miccoli S; Mirabelli D; Bracco C; Righi L; Boldorini R; Papotti M; Matullo G; Magnani C; Pasini B; Dianzani I
Cancer Lett; 2016 Aug; 378(2):120-30. PubMed ID: 27181379
[TBL] [Abstract][Full Text] [Related]
18. Mutation analysis in malignant melanoma.
Gaiser MR; Stadler R; Schirmacher P; Dietel M; Enk A
J Dtsch Dermatol Ges; 2013 May; 11 Suppl 4():2-10. PubMed ID: 23721634
[No Abstract] [Full Text] [Related]
19. Characteristics of Familial Melanoma in Valencia, Spain, Based on the Presence of CDKN2A Mutations and MC1R Variants.
Huerta C; Garcia-Casado Z; Bañuls J; Moragon M; Oliver V; Unamuno B; Requena C; Kumar R; Nagore E
Acta Derm Venereol; 2018 Apr; 98(5):512-516. PubMed ID: 29405243
[TBL] [Abstract][Full Text] [Related]
20. Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms.
Miller CJ; Cheung M; Sharma A; Clarke L; Helm K; Mauger D; Robertson GP
J Invest Dermatol; 2004 Nov; 123(5):990-2. PubMed ID: 15482489
[No Abstract] [Full Text] [Related]
[Next] [New Search]
